T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice.
Identifieur interne : 001669 ( PubMed/Curation ); précédent : 001668; suivant : 001670T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice.
Auteurs : Jincun Zhao [États-Unis] ; Jingxian Zhao ; Stanley PerlmanSource :
- Journal of virology [ 1098-5514 ] ; 2010.
Descripteurs français
- KwdFr :
- Analyse de survie, Animaux, Lymphocytes T (immunologie), Poumon (virologie), Rate (immunologie), Souris, Souris SCID, Souris de lignée BALB C, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (anatomopathologie), Syndrome respiratoire aigu sévère (immunologie), Transfert adoptif, Vaccins antiviraux (administration et posologie), Vaccins antiviraux (immunologie), Virus du SRAS (immunologie).
- MESH :
- administration et posologie : Vaccins antiviraux.
- anatomopathologie : Syndrome respiratoire aigu sévère.
- immunologie : Lymphocytes T, Rate, Syndrome respiratoire aigu sévère, Vaccins antiviraux, Virus du SRAS.
- virologie : Poumon.
- Analyse de survie, Animaux, Souris, Souris SCID, Souris de lignée BALB C, Syndrome respiratoire aigu sévère, Transfert adoptif.
English descriptors
- KwdEn :
- Adoptive Transfer, Animals, Lung (virology), Mice, Mice, Inbred BALB C, Mice, SCID, SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (pathology), Severe Acute Respiratory Syndrome (prevention & control), Spleen (immunology), Survival Analysis, T-Lymphocytes (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Viral Vaccines.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome, Spleen, T-Lymphocytes, Viral Vaccines.
- pathology : Severe Acute Respiratory Syndrome.
- prevention & control : Severe Acute Respiratory Syndrome.
- virology : Lung.
- Adoptive Transfer, Animals, Mice, Mice, Inbred BALB C, Mice, SCID, Survival Analysis.
Abstract
A dysregulated innate immune response and exuberant cytokine/chemokine expression are believed to be critical factors in the pathogenesis of severe acute respiratory syndrome (SARS), caused by a coronavirus (SARS-CoV). However, we recently showed that inefficient immune activation and a poor virus-specific T cell response underlie severe disease in SARS-CoV-infected mice. Here, we extend these results to show that virus-specific T cells, in the absence of activation of the innate immune response, were sufficient to significantly enhance survival and diminish clinical disease. We demonstrated that T cells are responsible for virus clearance, as intravenous adoptive transfer of SARS-CoV-immune splenocytes or in vitro-generated T cells to SCID or BALB/c mice enhanced survival and reduced virus titers in the lung. Enhancement of the number of virus-specific CD8 T cells by immunization with SARS-CoV peptide-pulsed dendritic cells also resulted in a robust T cell response, earlier virus clearance, and increased survival. These studies are the first to show that T cells play a crucial role in SARS-CoV clearance and that a suboptimal T cell response contributes to the pathological changes observed in SARS. They also provide a new approach to SARS vaccine design.
DOI: 10.1128/JVI.01049-10
PubMed: 20610717
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001669
Links to Exploration step
pubmed:20610717Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice.</title><author><name sortKey="Zhao, Jincun" sort="Zhao, Jincun" uniqKey="Zhao J" first="Jincun" last="Zhao">Jincun Zhao</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, University of Iowa, 3-712 Bowen Science Building, 51 Newton Road, Iowa City, IA 52242, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Microbiology, University of Iowa, 3-712 Bowen Science Building, 51 Newton Road, Iowa City, IA 52242</wicri:regionArea></affiliation></author><author><name sortKey="Zhao, Jingxian" sort="Zhao, Jingxian" uniqKey="Zhao J" first="Jingxian" last="Zhao">Jingxian Zhao</name></author><author><name sortKey="Perlman, Stanley" sort="Perlman, Stanley" uniqKey="Perlman S" first="Stanley" last="Perlman">Stanley Perlman</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20610717</idno><idno type="pmid">20610717</idno><idno type="doi">10.1128/JVI.01049-10</idno><idno type="wicri:Area/PubMed/Corpus">001669</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001669</idno><idno type="wicri:Area/PubMed/Curation">001669</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001669</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice.</title><author><name sortKey="Zhao, Jincun" sort="Zhao, Jincun" uniqKey="Zhao J" first="Jincun" last="Zhao">Jincun Zhao</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, University of Iowa, 3-712 Bowen Science Building, 51 Newton Road, Iowa City, IA 52242, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Microbiology, University of Iowa, 3-712 Bowen Science Building, 51 Newton Road, Iowa City, IA 52242</wicri:regionArea></affiliation></author><author><name sortKey="Zhao, Jingxian" sort="Zhao, Jingxian" uniqKey="Zhao J" first="Jingxian" last="Zhao">Jingxian Zhao</name></author><author><name sortKey="Perlman, Stanley" sort="Perlman, Stanley" uniqKey="Perlman S" first="Stanley" last="Perlman">Stanley Perlman</name></author></analytic><series><title level="j">Journal of virology</title><idno type="eISSN">1098-5514</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adoptive Transfer</term><term>Animals</term><term>Lung (virology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Mice, SCID</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (pathology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Spleen (immunology)</term><term>Survival Analysis</term><term>T-Lymphocytes (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Analyse de survie</term><term>Animaux</term><term>Lymphocytes T (immunologie)</term><term>Poumon (virologie)</term><term>Rate (immunologie)</term><term>Souris</term><term>Souris SCID</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (anatomopathologie)</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Transfert adoptif</term><term>Vaccins antiviraux (administration et posologie)</term><term>Vaccins antiviraux (immunologie)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Lymphocytes T</term><term>Rate</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term><term>Spleen</term><term>T-Lymphocytes</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Poumon</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lung</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adoptive Transfer</term><term>Animals</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Mice, SCID</term><term>Survival Analysis</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse de survie</term><term>Animaux</term><term>Souris</term><term>Souris SCID</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère</term><term>Transfert adoptif</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A dysregulated innate immune response and exuberant cytokine/chemokine expression are believed to be critical factors in the pathogenesis of severe acute respiratory syndrome (SARS), caused by a coronavirus (SARS-CoV). However, we recently showed that inefficient immune activation and a poor virus-specific T cell response underlie severe disease in SARS-CoV-infected mice. Here, we extend these results to show that virus-specific T cells, in the absence of activation of the innate immune response, were sufficient to significantly enhance survival and diminish clinical disease. We demonstrated that T cells are responsible for virus clearance, as intravenous adoptive transfer of SARS-CoV-immune splenocytes or in vitro-generated T cells to SCID or BALB/c mice enhanced survival and reduced virus titers in the lung. Enhancement of the number of virus-specific CD8 T cells by immunization with SARS-CoV peptide-pulsed dendritic cells also resulted in a robust T cell response, earlier virus clearance, and increased survival. These studies are the first to show that T cells play a crucial role in SARS-CoV clearance and that a suboptimal T cell response contributes to the pathological changes observed in SARS. They also provide a new approach to SARS vaccine design.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20610717</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>84</Volume><Issue>18</Issue><PubDate><Year>2010</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J. Virol.</ISOAbbreviation></Journal><ArticleTitle>T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice.</ArticleTitle><Pagination><MedlinePgn>9318-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01049-10</ELocationID><Abstract><AbstractText>A dysregulated innate immune response and exuberant cytokine/chemokine expression are believed to be critical factors in the pathogenesis of severe acute respiratory syndrome (SARS), caused by a coronavirus (SARS-CoV). However, we recently showed that inefficient immune activation and a poor virus-specific T cell response underlie severe disease in SARS-CoV-infected mice. Here, we extend these results to show that virus-specific T cells, in the absence of activation of the innate immune response, were sufficient to significantly enhance survival and diminish clinical disease. We demonstrated that T cells are responsible for virus clearance, as intravenous adoptive transfer of SARS-CoV-immune splenocytes or in vitro-generated T cells to SCID or BALB/c mice enhanced survival and reduced virus titers in the lung. Enhancement of the number of virus-specific CD8 T cells by immunization with SARS-CoV peptide-pulsed dendritic cells also resulted in a robust T cell response, earlier virus clearance, and increased survival. These studies are the first to show that T cells play a crucial role in SARS-CoV clearance and that a suboptimal T cell response contributes to the pathological changes observed in SARS. They also provide a new approach to SARS vaccine design.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jincun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Microbiology, University of Iowa, 3-712 Bowen Science Building, 51 Newton Road, Iowa City, IA 52242, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jingxian</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Perlman</LastName><ForeName>Stanley</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AI060699</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI079429</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56AI079429</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019264" MajorTopicYN="N">Adoptive Transfer</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013154" MajorTopicYN="N">Spleen</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20610717</ArticleId><ArticleId IdType="pii">JVI.01049-10</ArticleId><ArticleId IdType="doi">10.1128/JVI.01049-10</ArticleId><ArticleId IdType="pmc">PMC2937604</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Immunogenetics. 1999 Nov;50(3-4):213-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10602881</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2010 Feb;6(2):e1000756</Citation><ArticleIdList><ArticleId IdType="pubmed">20140198</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods. 2003 Mar;29(3):270-81</Citation><ArticleIdList><ArticleId IdType="pubmed">12725792</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2003 Jun 21;326(7403):1358-62</Citation><ArticleIdList><ArticleId IdType="pubmed">12816821</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2003 Jul 1;171(1):27-31</Citation><ArticleIdList><ArticleId IdType="pubmed">12816979</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2004 Jan;10(1):20-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15078592</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunogenetics. 2004 Sep;56(6):405-19</Citation><ArticleIdList><ArticleId IdType="pubmed">15349703</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 1989 Aug 1;170(2):499-509</Citation><ArticleIdList><ArticleId IdType="pubmed">2526847</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1990 Sep;64(9):4589-92</Citation><ArticleIdList><ArticleId IdType="pubmed">2166833</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1992 Aug 15;149(4):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">1354233</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol Methods. 1994 Sep 14;174(1-2):83-93</Citation><ArticleIdList><ArticleId IdType="pubmed">8083541</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunogenetics. 1995;41(4):178-228</Citation><ArticleIdList><ArticleId IdType="pubmed">7890324</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 1995 Apr 1;181(4):1275-83</Citation><ArticleIdList><ArticleId IdType="pubmed">7699319</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1997 Dec 1;159(11):5197-200</Citation><ArticleIdList><ArticleId IdType="pubmed">9548456</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2005 Apr 25;335(1):34-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15823604</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2005 Jul;11(7):748-56</Citation><ArticleIdList><ArticleId IdType="pubmed">15951824</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Oct 28;310(5748):676-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16195424</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Feb;81(4):1848-57</Citation><ArticleIdList><ArticleId IdType="pubmed">17151094</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 May;81(9):4694-700</Citation><ArticleIdList><ArticleId IdType="pubmed">17314167</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2007 Jan;3(1):e5</Citation><ArticleIdList><ArticleId IdType="pubmed">17222058</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2007 Jul 6;358(3):716-21</Citation><ArticleIdList><ArticleId IdType="pubmed">17506989</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Aug;81(16):8692-706</Citation><ArticleIdList><ArticleId IdType="pubmed">17537853</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 Sep 28;25(39-40):6981-91</Citation><ArticleIdList><ArticleId IdType="pubmed">17709158</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2008 Apr;8(4):247-58</Citation><ArticleIdList><ArticleId IdType="pubmed">18323851</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 2008 Jun;172(6):1625-37</Citation><ArticleIdList><ArticleId IdType="pubmed">18467696</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2008 Oct;82(19):9465-76</Citation><ArticleIdList><ArticleId IdType="pubmed">18632870</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2008 Dec;4(12):e1000240</Citation><ArticleIdList><ArticleId IdType="pubmed">19079579</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2009 Mar;15(3):277-84</Citation><ArticleIdList><ArticleId IdType="pubmed">19234462</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Immunol. 2009;27:485-517</Citation><ArticleIdList><ArticleId IdType="pubmed">19132915</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2009 Jul;83(14):7062-74</Citation><ArticleIdList><ArticleId IdType="pubmed">19420084</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2009 Oct;5(10):e1000636</Citation><ArticleIdList><ArticleId IdType="pubmed">19851468</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2010 Feb;84(3):1289-301</Citation><ArticleIdList><ArticleId IdType="pubmed">19906920</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2003 Feb;18(2):265-77</Citation><ArticleIdList><ArticleId IdType="pubmed">12594953</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001669 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001669 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:20610717
|texte= T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:20610717" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |